Telix Pharmaceuticals Ltd (ASX: TLX) shares have dropped just over 8% to $14.44 at the time of writing on Wednesday.

After hitting a three-year low in mid-February the ASX healthcare shares rebounded strongly and surged 83% within two months.

Since then they’ve been pretty volatile, swinging between $12.20 and $17.85 in mid-September.

But, even after the latest decline the shares are up around 27% for the year-to-date, although they’re 14% lower than 2 months ago.

Today’s crash follows the company’s third-quarter earnings for FY26, which it posted to the ASX ahead of the market open this morning.

Clearly the announcement has spooked investors, with many rushing for the exits today.

What did Telix report?

The company posted its third-quarter FY26 results this morning for the period ending 30th of September.

Telix posted a 19% increase in its revenue versus the same period in 2025 but down 1% from the previous quarter, broadly in line with expectations.

Revenue in the company’s Precision Medicine business jumped 30% versus the same period in FY25, but flat on the second quarter of FY26. 

The company said it will continue to expand its product pipeline, advancing multiple late-stage trials in prostate, brain, and kidney cancer. 

Telix reaffirmed that its FY26 revenue and other income is expected to be in excess of US$1 billion, with revenue tracking in line with the upper end of guidance, driven by growth in its Precision Medicine business and improved commercial momentum for new products.

The company also revised its FY26 research and development expenditure guidance range to US$240 million to US$260 million, from US$230 million to $270 million previously. It also confirmed that its pipeline is expanding, with trial results and regulatory results in progress.

So, why are the shares falling?

Telix’s latest update is positive, so today’s decline mostly looks like the result of profit-taking investors taking their gains off the table after the shares spiked to an annual high last month.

It also looked like much of the good news out of the announcement was already priced into the latest share price.

Telix’s narrowed research and development expenditure also suggests that costs could be running a bit higher than it previously expected.

What does the outlook look like for Telix shares?

The experts are even more bullish on Telix shares over the next 12 months. TradingView data shows the majority (14 out of 15) have a buy/strong buy rating on the ASX healthcare stock. One more rates the shares as a hold.

And these all agree a significant upside ahead after today’s crash. 

The $26.44 average target price implies an upside of around 80% at the time of writing. 

Meanwhile, the maximum target price of $32.07 now implies a 119% upside over the next 12 months, at the time of writing.

The post Telix shares crashing 8% today: What happened? appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances
• Here are the top 10 ASX 200 shares today
• Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?
• UBS thinks Telix Pharmaceuticals shares will go how high?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Blackpearl Group Ltd (ASX: BPG) have fallen almost 80% over the past 12 months, but the analyst team at Bell Potter believes they can bounce back strongly.

The broker has just issued a new research note on the company with a speculative buy recommendation, and while they have cut their share price target almost in half, they still expect the company to increase substantially in value.

I’ll get to the specifics of their share price target shortly.

First, let’s look at Blackpearl Group’s most recent trading update issued just this week.

Business model evolving

The company said in a statement to the ASX that it now expects profitability on an EBITDA basis in FY28, after narrowing its quarterly loss by a third to $2.97 million.

The cloud technology company said it had reduced its cost base by about 27% compared with the fourth quarter of FY26, or about $9.4 million on an annualised basis.

During the quarter, the company had also struck a non-binding agreement with “one of the largest data providers in the United States: a private company serving Fortune 500 companies with B2B intent data and demand generation”.

Blackpearl Group added:

The partner works only inside a large enterprise customer profile and does not service SME US businesses. That demand is now referred to Blackpearl, which delivers data and platform as a service to those customers under a revenue share between 20% and 40%, depending on the type of deal. Blackpearl owns the customer relationship. The partner has an identified referral pipeline of 70+ companies, with typical deal sizes of US$10,000 to US$30,000 per month.

Blackpearl said since the partner originates the relationship, there was no upfront customer acquisition cost and payback is immediate.

They added:

Gross margin is high and the incremental cost to serve is low, so revenue from this channel flows largely through to EBITDAF. Onboarding is fast: Blackpearl already holds the underlying data asset, and the Pearl Engine applies its models over it. The partnership validates the Group’s DaaS and PaaS strategy, where Blackpearl’s data intelligence powers other companies’ products and revenue systems. Further distribution agreements are in negotiation.

ASX tech shares looking cheap

Bell Potter said the change in Blackpearl’s revenue model meant the broker had changed how it valued the company, moving from a recurring revenue model to a discounted cash flow model.

This had led to a drop in the share price target from $1.20 to 65 cents, compared to the current share price of 19 cents.

If achieved this would be a 242.1% return.

The post This small-cap ASX tech stock could more than triple in value: Broker appeared first on The Motley Fool Australia.

More reading

• Are NDQ and these Betashares ETFs buys for Australian investors?
• Could WiseTech shares smash past $100 in the next 12 months?
• Telix shares crashing 8% today: What happened?
• 4 hugely undervalued ASX shares I’d buy with $5,000 
• I looked for ASX shares that could double their dividends by 2036. Here’s what I found

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX shares have come under more downward pressure today, dragged lower by softer commodity prices and a huge crash in the NextDC Ltd (ASX: NXT) share price.

If I had a spare $5,000, here are four significantly undervalued ASX shares that I’d look to buy.

Elevra Lithium Ltd (ASX: ELV)

Elevra shares are down around 2% at the time of writing, to $3.74. The shares are now down around 53% year to date and roughly 14% lower than a year ago. The lithium shares have been hit by lithium price headwinds over the past few months. Lithium has fallen to around CNY 100,000 per tonne this week, down from around CNY 160,000 in early September, due to softer demand and a spike in supply. But the experts forecast a significant turnaround over the next 12 months. Market Index shows the majority of brokers have a buy rating on the shares, and the $13.05 average target price implies an upside of around 250% at the time of writing.

Deep Yellow Ltd (ASX: DYL)

Deep Yellow shares have climbed around 1% to 74 cents a piece at the time of writing. Today’s increase is great news, but it barely makes a dent in the huge losses incurred this year. The ASX uranium shares have fallen around 11% over the past week, and are now down a huge 62% year to date. Rising bond yields and high interest rates have acted as strong headwinds for Deep Yellow. The company also recently announced it had delayed construction at its Tumas project because current equity market conditions don’t support raising the capital it needs. But the experts are bullish, believing the decline is temporary and that there is strong upside ahead. Market Index data shows that the majority of brokers have a buy rating on Deep Yellow shares. The $2.25 average target price implies a 207% upside, at the time of writing.

NextDC Ltd (ASX: NXT) 

NextDC shares have crashed 41% on Wednesday to just $5.41 following the company’s latest market update. The data centre operator announced this morning that there is a delay in delivering electricity to its M3 Melbourne data centre, which will then delay its ability to deliver and bill customers for contracted capacity. This has forced management to make substantial reductions to its FY27 guidance. Guidance for underlying EBITDA has been revised to between $245 million and $265 million, down from $385 million to $410 million previously. Net revenue guidance has been revised to between $475 million and $500 million, down from $615 million and $640 million. But expert forecasts still remain intact. Market Index shows the majority of brokers have a strong buy rating on the ASX shares. The $19.15 average target price implies a potential 250% upside, at the time of writing.

Siteminder Ltd (ASX: SDR)

Siteminder shares are unchanged at $2.68 at the time of writing on Wednesday. However, the shares are down about 56% year to date. SiteMinder shares were hit by a disappointing FY26 results announcement in mid-August. The company posted a 22% increase in revenue and a 96.5% increase in EBITDA. Its net loss also improved to $11.3 million, down from $24.5 million in FY25. The company also said it expects its adjusted EBITDA margin to keep expanding in FY27 and reach the mid-20% range by FY30. On the surface, the results look good, but investors are concerned about the conservative growth outlook. The experts are less hesitant. Market Index shows the majority of brokers have a strong buy rating on the ASX shares. The $5.40 average target price implies an upside of around 101% at the time of writing.

The post 4 hugely undervalued ASX shares I'd buy with $5,000  appeared first on The Motley Fool Australia.

More reading

• Should I buy NEXTDC shares after today’s 45% crash?
• NEXTDC slashes FY27 guidance after M3 Melbourne power delay
• Buy, hold, sell: Deep Yellow, PLS, Pro Medicus shares
• I looked at the bear case for these 3 ASX shares, and came to a different conclusion. Here’s why
• This ASX uranium company is set to surge: Brokers

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended SiteMinder. The Motley Fool Australia has positions in and has recommended SiteMinder. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.